

# Christopher P Crum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1315028/publications.pdf>

Version: 2024-02-01

140  
papers

18,571  
citations

16451  
64  
h-index

14208  
128  
g-index

142  
all docs

142  
docs citations

142  
times ranked

15951  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular catastrophe, the peritoneal cavity and ovarian cancer prevention. Journal of Pathology, 2022, , .	4.5	2
2	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Research, 2021, 81, 158-173.	0.9	85
3	Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Modern Pathology, 2021, 34, 613-626.	5.5	11
4	Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1â€“AKTâ€“p53 Interactions. Cancers, 2021, 13, 2195.	3.7	0
5	Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers, 2021, 13, 3218.	3.7	2
6	Interobserver reproducibility of the diagnosis of differentiated exophytic vulvar intraepithelial lesion (DEVIL) and the distinction from its mimics. Histopathology, 2021, 79, 957-965.	2.9	11
7	Evidence for a Novel Endometrioid Carcinogenic Sequence in the Fallopian Tube With Unique Beta-Catenin Expression. International Journal of Gynecological Pathology, 2020, 39, 163-169.	1.4	6
8	MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread. Oncogene, 2020, 39, 4045-4060.	5.9	13
9	The Cellular Origin of Barrettâ€™s Esophagus and Its Stem Cells. Advances in Experimental Medicine and Biology, 2019, 1123, 55-69.	1.6	11
10	Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia. International Journal of Gynecological Pathology, 2019, 38, 443-448.	1.4	8
11	The fallopian tube, â€œprecursor escapeâ€ and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecologic Oncology, 2019, 152, 426-433.	1.4	77
12	A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. British Journal of Cancer, 2018, 118, 1302-1312.	6.4	30
13	SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. Modern Pathology, 2018, 31, 1442-1456.	5.5	128
14	Origin of clear cell carcinoma: nature or nurture?. Journal of Pathology, 2018, 244, 131-134.	4.5	10
15	Frontiers in the Pathology and Pathogenesis of Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 915-928.	2.2	12
16	Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis. Cancers, 2018, 10, 468.	3.7	31
17	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discovery, 2018, 8, 1404-1421.	9.4	311
18	Cervical Squamous Neoplasia. , 2018, , 298-374.		11

#	ARTICLE	IF	CITATIONS
19	The Fallopian Tube and Broad Ligament. , 2018, , 716-760.		1
20	Assessing Pelvic Epithelial Cancer Risk and Intercepting Early Malignancy. , 2018, , 844-864.		0
21	The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. , 2018, , 865-948.		1
22	Surgical prevention strategies in ovarian cancer. Gynecologic Oncology, 2018, 151, 166-175.	1.4	38
23	Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. Journal of Pathology, 2018, 246, 344-351.	4.5	55
24	Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract. American Journal of Surgical Pathology, 2018, 42, 227-233.	3.7	110
25	Serous tubal intraepithelial neoplasia: the concept and its application. Modern Pathology, 2017, 30, 710-721.	5.5	77
26	First International Consensus Report on Adnexal Masses: Management Recommendations. Journal of Ultrasound in Medicine, 2017, 36, 849-863.	1.7	72
27	Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. Gynecologic Oncology, 2017, 146, 69-73.	1.4	34
28	Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. Journal of Pathology, 2017, 241, 522-533.	4.5	32
29	Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Modern Pathology, 2017, 30, 448-458.	5.5	72
30	Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis. Viruses, 2017, 9, 85.	3.3	29
31	Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. ELife, 2017, 6, .	6.0	106
32	Comprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian Women. Journal of Global Oncology, 2017, 3, 227-234.	0.5	10
33	Prognostic importance of p16 status for women with vulvar squamous cell carcinoma (SCC) treated with radiotherapy.. Journal of Clinical Oncology, 2017, 35, 5599-5599.	1.6	0
34	<i>In vitro</i> and <i>in vivo</i> correlates of physiological and neoplastic human Fallopian tube stem cells. Journal of Pathology, 2016, 238, 519-530.	4.5	68
35	Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Modern Pathology, 2016, 29, 893-903.	5.5	33
36	Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecologic Oncology, 2016, 142, 293-298.	1.4	87

#	ARTICLE	IF	CITATIONS
37	p16ink4 and cytokeratin 7 immunostaining in predicting HSIL outcome for low-grade squamous intraepithelial lesions: a case series, literature review and commentary. <i>Modern Pathology</i> , 2016, 29, 1501-1510.	5.5	26
38	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	1.5	7
39	Mutational spectrum of Barrett's stem cells suggests paths to initiation of a precancerous lesion. <i>Nature Communications</i> , 2016, 7, 10380.	12.8	57
40	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. <i>JAMA Oncology</i> , 2016, 2, 518.	7.1	121
41	Preventing Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 198-199.	1.6	7
42	Response to "Two major pathways of recurrent high-grade squamous intraepithelial lesions of the cervix". <i>International Journal of Cancer</i> , 2015, 137, 2522-2523.	5.1	0
43	Evidence for a Dualistic Model of High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 287-293.	3.7	96
44	Cloning and variation of ground state intestinal stem cells. <i>Nature</i> , 2015, 522, 173-178.	27.8	156
45	Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. <i>International Journal of Cancer</i> , 2015, 137, 776-783.	5.1	39
46	Salpingectomy as a Potential Ovarian Cancer Risk-Reducing Procedure. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju490-dju490.	6.3	10
47	Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. <i>Modern Pathology</i> , 2015, 28, 994-1000.	5.5	84
48	Squamocolumnar junction ablation "tying up loose ends". <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 378-380.	27.6	16
49	Ovarian cancer survival by tumor dominance, a surrogate for site of origin. <i>Cancer Causes and Control</i> , 2015, 26, 601-608.	1.8	4
50	Carcinogenic HPV infection in the cervical squamocolumnar junction. <i>Journal of Pathology</i> , 2015, 236, 265-271.	4.5	59
51	Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. <i>Gynecologic Oncology</i> , 2015, 139, 104-111.	1.4	47
52	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S111-22.	2.3	70
53	Molecular changes in endometriosis-associated ovarian clear cell carcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1831-1842.	2.8	44
54	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. <i>Nature Communications</i> , 2015, 6, 7419.	12.8	149

#	ARTICLE	IF	CITATIONS
55	p63+Krt5+ distal airway stem cells are essential for lung regeneration. <i>Nature</i> , 2015, 517, 616-620.	27.8	433
56	Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. <i>International Journal of Cancer</i> , 2015, 136, 1043-1052.	5.1	29
57	The <scp>PAX2</scp>-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. <i>Journal of Pathology</i> , 2014, 234, 478-487.	4.5	30
58	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , 2014, 506, 371-375.	27.8	708
59	Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. <i>Gynecologic Oncology</i> , 2014, 132, 280-286.	1.4	74
60	BMP4-directed trophoblast differentiation of human embryonic stem cells is mediated through a $\beta$ -Np63+ cytotrophoblast stem cell state. <i>Development (Cambridge)</i> , 2013, 140, 3965-3976.	2.5	111
61	A novel blueprint for "top down" differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. <i>Journal of Pathology</i> , 2013, 229, 460-468.	4.5	81
62	Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. <i>International Journal of Cancer</i> , 2013, 133, 730-739.	5.1	18
63	Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. <i>Cancer Cell</i> , 2013, 24, 751-765.	16.8	488
64	Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles. <i>Gynecologic Oncology</i> , 2013, 128, 488-492.	1.4	16
65	Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. <i>Journal of Pathology</i> , 2013, 231, 402-412.	4.5	68
66	Differential Expression of p-ERM, a Marker of Cell Polarity, in Benign and Neoplastic Oviductal Epithelium. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 345-352.	1.4	7
67	Cervical Squamocolumnar Junction-specific Markers Define Distinct, Clinically Relevant Subsets of Low-grade Squamous Intraepithelial Lesions. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1311-1318.	3.7	60
68	Laboratory Management of Cervical Intraepithelial Neoplasia. <i>Advances in Anatomic Pathology</i> , 2013, 20, 86-94.	4.3	12
69	Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. <i>PLoS ONE</i> , 2013, 8, e80314.	2.5	43
70	The Oviduct and Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 24-35.	1.1	65
71	Digital quantification of precursor frequency in the fallopian tube and its significance. <i>Modern Pathology</i> , 2012, 25, 1654-1661.	5.5	8
72	PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. <i>Modern Pathology</i> , 2012, 25, 449-455.	5.5	47

#	ARTICLE	IF	CITATIONS
73	BRCA, the Oviduct, and the Space and Time Continuum of Pelvic Serous Carcinogenesis. International Journal of Gynecological Cancer, 2012, 22, S29-S34.	2.5	49
74	Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2012, 119, S118-29.	2.3	194
75	A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10516-10521.	7.1	350
76	Cellular Origin of Barrett's Esophagus: Controversy and Therapeutic Implications. Gastroenterology, 2012, 142, 1424-1430.	1.3	42
77	Residual Embryonic Cells as Precursors of a Barrett's-like Metaplasia. Cell, 2011, 145, 1023-1035.	28.9	292
78	Distal Airway Stem Cells Yield Alveoli In Vitro and during Lung Regeneration following H1N1 Influenza Infection. Cell, 2011, 147, 525-538.	28.9	510
79	STICS SCOUTs and p53 signatures a new language for pelvic serous carcinogenesis. Frontiers in Bioscience - Elite, 2011, E3, 625-634.	1.8	90
80	Fallopian Tube Correlates of Ovarian Serous Borderline Tumors. American Journal of Surgical Pathology, 2011, 35, 1759-1765.	3.7	59
81	Response to Gilks et al. Modern Pathology, 2011, 24, 1282-1283.	5.5	3
82	The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Modern Pathology, 2011, 24, 152-156.	5.5	41
83	The Fallopian Tube and Broad Ligament. , 2011, , 640-678.		1
84	Serous Tubal Intraepithelial Carcinoma: Diagnostic Reproducibility and its Implications. International Journal of Gynecological Pathology, 2010, 29, 310-314.	1.4	83
85	Bringing the p53 signature into focus. Cancer, 2010, 116, 5119-5121.	4.1	11
86	The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. Journal of Pathology, 2010, 220, 17-23.	4.5	41
87	Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. Journal of Pathology, 2010, 222, 110-116.	4.5	129
88	Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. Modern Pathology, 2010, 23, 404-412.	5.5	115
89	High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Modern Pathology, 2010, 23, 1316-1324.	5.5	109
90	p63 in Epithelial Survival, Germ Cell Surveillance, and Neoplasia. Annual Review of Pathology: Mechanisms of Disease, 2010, 5, 349-371.	22.4	191

#	ARTICLE	IF	CITATIONS
91	Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. <i>Gynecologic Oncology</i> , 2009, 115, 108-111.	1.4	24
92	Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. <i>Modern Pathology</i> , 2009, 22, 345-350.	5.5	61
93	Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. <i>Modern Pathology</i> , 2009, 22, 985-988.	5.5	43
94	Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. <i>Molecular Oncology</i> , 2009, 3, 165-170.	4.6	143
95	Serous Tubal Intraepithelial Carcinoma and the Dominant Ovarian Mass. <i>American Journal of Surgical Pathology</i> , 2009, 33, 376-383.	3.7	126
96	Coexisting Intraepithelial Serous Carcinomas of the Endometrium and Fallopian Tube: Frequency and Potential Significance. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 308-315.	1.4	86
97	Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. <i>Diagnostic Histopathology</i> , 2008, 14, 352-365.	0.4	28
98	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. <i>Gynecologic Oncology</i> , 2008, 109, 168-173.	1.4	268
99	Risk factors for a serous cancer precursor (p53 signature) in women with inherited BRCA mutations. <i>Gynecologic Oncology</i> , 2008, 111, 226-232.	1.4	77
100	Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2008, 26, 4160-4165.	1.6	317
101	New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. <i>Journal of Clinical Oncology</i> , 2008, 26, 5284-5293.	1.6	362
102	Serous Carcinogenesis in the Fallopian Tube. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 1-9.	1.4	275
103	Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction. <i>Journal of Clinical Oncology</i> , 2007, 25, 3985-3990.	1.6	453
104	Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer. <i>Clinical Medicine and Research</i> , 2007, 5, 35-44.	0.8	301
105	Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship. <i>American Journal of Surgical Pathology</i> , 2007, 31, 161-169.	3.7	980
106	The distal fallopian tube: a new model for pelvic serous carcinogenesis. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 3-9.	2.0	425
107	p63 Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia. <i>Cell</i> , 2007, 129, 523-536.	28.9	783
108	A unifying concept of trophoblastic differentiation and malignancy defined by biomarker expression. <i>Human Pathology</i> , 2007, 38, 1003-1013.	2.0	78

#	ARTICLE	IF	CITATIONS
109	A multi-step model of pelvic serous carcinogenesis that originates in the distal fallopian tube from a novel precursor lesion.. FASEB Journal, 2007, 21, A77.	0.5	0
110	Advances in the Recognition of Tubal Intraepithelial Carcinoma. Advances in Anatomic Pathology, 2006, 13, 1-7.	4.3	144
111	The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome. American Journal of Surgical Pathology, 2006, 30, 230-236.	3.7	797
112	p63 protects the female germ line during meiotic arrest. Nature, 2006, 444, 624-628.	27.8	479
113	Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. Cancer Research, 2005, 65, 2162-2169.	0.9	484
114	Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Human Pathology, 2005, 36, 154-161.	2.0	49
115	Dynamics of Human Papillomavirus Infection between Biopsy and Excision of Cervical Intraepithelial Neoplasia: Results from the ZYC101a Protocol. Journal of Infectious Diseases, 2004, 189, 1348-1354.	4.0	26
116	Expression of candidate tumor markers in ovarian carcinoma and benign ovary: Evidence for a link between epithelial phenotype and neoplasia. Human Pathology, 2004, 35, 1014-1021.	2.0	69
117	p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Human Pathology, 2004, 35, 1477-1483.	2.0	117
118	Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. American Journal of Obstetrics and Gynecology, 2003, 188, 916-926.	1.3	152
119	Symposium Part 1: Should the Bethesda System Terminology be Used in Diagnostic Surgical Pathology?: Point. International Journal of Gynecological Pathology, 2003, 22, 5-12.	1.4	36
120	Hertig and Beyond: A Systematic and Practical Approach to the Endometrial Biopsy. Advances in Anatomic Pathology, 2003, 10, 301-318.	4.3	27
121	Vaccines for Cervical Cancer. Cancer Journal (Sudbury, Mass ), 2003, 9, 368-376.	2.0	12
122	p63 Coordinates Anogenital Modeling and Epithelial Cell Differentiation in the Developing Female Urogenital Tract. American Journal of Pathology, 2002, 161, 1111-1117.	3.8	106
123	Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer. American Journal of Pathology, 2002, 161, 1199-1206.	3.8	240
124	Human papillomaviruses. Applications, caveats and prevention. Journal of reproductive medicine, The, 2002, 47, 519-28; discussion 528-9.	0.2	3
125	Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: A study of 250 cases. Human Pathology, 2001, 32, 479-486.	2.0	153
126	Ki-67, Cyclin E, and p16 INK4 Are Complimentary Surrogate Biomarkers for Human Papilloma Virus-Related Cervical Neoplasia. American Journal of Surgical Pathology, 2001, 25, 884-891.	3.7	405



#	ARTICLE	IF	CITATIONS
127	Expression of the p53 Homologue p63 in Early Cervical Neoplasia. Gynecologic Oncology, 2001, 80, 24-29.	1.4	131
128	Identification of a Basal/Reserve Cell Immunophenotype in Benign and Neoplastic Endometrium: A Study with the p53 Homologue p63. Gynecologic Oncology, 2001, 80, 30-36.	1.4	74
129	Stratified Mucin-Producing Intraepithelial Lesions of the Cervix. American Journal of Surgical Pathology, 2000, 24, 1414-1419.	3.7	143
130	Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. , 2000, 190, 462-469.		171
131	Allelic Imbalance in Lichen Sclerosus, Hyperplasia, and Intraepithelial Neoplasia of the Vulva. Gynecologic Oncology, 2000, 77, 171-176.	1.4	78
132	Contemporary Theories of Cervical Carcinogenesis: The Virus, the Host, and the Stem Cell. Modern Pathology, 2000, 13, 243-251.	5.5	58
133	p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature, 1999, 398, 714-718.	27.8	2,082
134	Allelic Loss in Human Papillomavirus-Positive and -Negative Vulvar Squamous Cell Carcinomas. American Journal of Pathology, 1999, 154, 1009-1015.	3.8	42
135	Cytologic correlates of papillary immature metaplasia (immature condyloma) of the cervix. Diagnostic Cytopathology, 1998, 18, 416-421.	1.0	18
136	Koilocytotic atypia in papanicolaou smears. , 1997, 81, 10-15.		22
137	Koilocytotic atypia in papanicolaou smears. Cancer, 1997, 81, 10-15.	4.1	4
138	Human Papillomavirus Type 16 Infection. International Journal of Gynecological Pathology, 1986, 5, 287-296.	1.4	19
139	Human Papillomavirus Type 16 and Early Cervical Neoplasia. New England Journal of Medicine, 1984, 310, 880-883.	27.0	416
140	Peritoneal and tubal serous carcinoma. , 0, , 111-120.		0